Supportive Care in Cancer

, Volume 27, Issue 1, pp 3–4 | Cite as

Letter to the editor—comments on Kleckner et al. (2018) “Effects of exercise during chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial”

  • J.K. VallanceEmail author
  • K.A. Bolam
Letter to the Editor

We read with interest the recent article by Kleckner et al. [1] examining the effects of a 6-week exercise program (EXCAP©®) among 355 cancer survivors (breast, lymphoma, colon, lung, and other) on chemotherapy-induced peripheral neuropathy (CIPN). We agree that CIPN is an important patient outcome in the exercise and cancer field. In their trial, the authors concluded “exercise appears to reduce CIPN symptoms in patients receiving taxane-, platinum-, or vinca alkaloid-based chemotherapy.” (p. 1019). In our opinion, while the study shows potentially positive trends, the conclusions drawn by the authors may be somewhat premature.

The authors stated, “Exercise reduced CIPN symptoms of hot/coldness in hands/feet (-0.46 units, p=0.045) and numbness and tingling (-0.42 units, p=0.061) compared to the control. Exercise reduced CIPN symptoms more for patients who were older (p=0.086), male (p=0.028), or had breast cancer (p=0.076).” (p. 1019). Table 2 and Figure 2 in the Kleckner et al....


Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Kleckner I, Kamen C, Gewandter JS, Mohile NA, Heckler CE, Culakova E, Fund C, Janelsins MC, Asare M, Po-Ju L, Reddy PS, Giguere J, Berenberg J, Kesler SR, Mustian KM (2018) Effects of exercise during chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial. Support Care Cancer 26:1019–1028CrossRefGoogle Scholar
  2. 2.
    Feise RJ (2002) Do multiple outcome measures require p-value adjustment? BMC Med Res Methodol 2:8CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Mendoza TR, Zhao F, Cleeland CS, Wagner LI, Patrick-Miller LJ, Fisch MJ (2013) The validity and utility of the M. D. Anderson Symptom Inventory in patients with breast cancer: evidence from the Symptom Outcomes and Practice Patterns Data from the Eastern Cooperative Oncology Group. Clin Breast Cancer 13(5):325–334CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Bao T, Basal C, Seluzicki C, Li SQ, Seidman AD, Mao JJ (2016) Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk. Breast Cancer Res Treat 159:327–333CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Cella D, Peterman A, Hudgens S, Webster K, Socinski MA (2003) Measuring the side effects of taxane therapy in oncology: the functional assessment of cancer therapy-taxane (FACT-Taxane). Cancer 98:822–831CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Faculty of Health DisciplinesAthabasca UniversityAthabascaCanada
  2. 2.Department of Neurobiology, Care Sciences and SocietyKarolinska InstitutetStockholmSweden

Personalised recommendations